Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo

Authors: Stine S. Jensen, Stine A. Petterson, Bo Halle, Charlotte Aaberg-Jessen, Bjarne W. Kristensen

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresistant brain tumor-initiating cells combined with the invasive properties of the tumors is believed to be critical for treatment resistance. In the present study, the aim was to investigate the effect of a novel therapeutic strategy using the lysosomotropic detergent siramesine on glioblastomas.

Methods

Standard glioma cell lines and patient-derived spheroids cultures with tumor-initiating stem-like cells were used to investigate effects of siramesine on proliferation and cell death. Responsible mechanisms were investigated by inhibitors of caspases and cathepsins. Effects of siramesine on migrating tumor cells were investigated by a flat surface migration assay and by implanting spheroids into organotypic rat brain slice cultures followed by confocal time-lapse imaging. Finally the effect of siramesine was investigated in an orthotopic mouse glioblastoma model. Results obtained in vitro and in vivo were confirmed by immunohistochemical staining of histological sections of spheroids, spheroids in brain slice cultures and tumors in mice brains.

Results

The results showed that siramesine killed standard glioma cell lines in vitro, and loss of acridine orange staining suggested a compromised lysosomal membrane. Co-treatment of the cell lines with inhibitors of caspases and cathepsins suggested differential involvement in cell death. Siramesine caused tumor cell death and reduced secondary spheroid formation of patient-derived spheroid cultures. In the flat surface migration model siramesine caused tumor cell death and inhibited tumor cell migration. This could not be reproduced in the organotypic three dimensional spheroid-brain slice culture model or in the mice xenograft model.

Conclusions

In conclusion the in vitro results obtained with tumor cells and spheroids suggest a potential of lysosomal destabilizing drugs in killing glioblastoma cells, but siramesine was without effect in the organotypic spheroid-brain slice culture model and the in vivo xenograft model.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed
2.
go back to reference Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522–6.CrossRefPubMedPubMedCentral Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522–6.CrossRefPubMedPubMedCentral
3.
go back to reference Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neuro-Oncol. 2004;70(2):217–28.CrossRef Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neuro-Oncol. 2004;70(2):217–28.CrossRef
4.
go back to reference Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434–51.CrossRefPubMed Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434–51.CrossRefPubMed
5.
go back to reference Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM, Salvesen GS, Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004;279(5):3578–87.CrossRefPubMed Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM, Salvesen GS, Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004;279(5):3578–87.CrossRefPubMed
6.
go back to reference Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004;23(16):2746–56.CrossRefPubMed Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004;23(16):2746–56.CrossRefPubMed
7.
go back to reference Sanchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J. The selective sigma2-ligand Lu 28–179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther. 1997;283(3):1323–32.PubMed Sanchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J. The selective sigma2-ligand Lu 28–179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther. 1997;283(3):1323–32.PubMed
8.
go back to reference Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs. 2001;2(2):266–70.PubMed Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs. 2001;2(2):266–70.PubMed
9.
go back to reference Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005;65(19):8975–83.CrossRefPubMed Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005;65(19):8975–83.CrossRefPubMed
10.
go back to reference Ostenfeld MS, Hoyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sorensen T, Nylandsted J, Farkas T, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy. 2008;4(4):487–99.CrossRefPubMed Ostenfeld MS, Hoyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sorensen T, Nylandsted J, Farkas T, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy. 2008;4(4):487–99.CrossRefPubMed
11.
go back to reference Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007;67(5):2217–25.CrossRefPubMed Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007;67(5):2217–25.CrossRefPubMed
12.
go back to reference Jensen SS, Aaberg-Jessen C, Andersen C, Schroder HD, Kristensen BW. Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. Neurosurgery. 2013;73(5):868–86. discussion 886.CrossRefPubMed Jensen SS, Aaberg-Jessen C, Andersen C, Schroder HD, Kristensen BW. Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. Neurosurgery. 2013;73(5):868–86. discussion 886.CrossRefPubMed
13.
go back to reference Aaberg-Jessen C, Norregaard A, Christensen K, Pedersen CB, Andersen C, Kristensen BW. Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int J Clin Exp Pathol. 2013;6(4):546–60.PubMedPubMedCentral Aaberg-Jessen C, Norregaard A, Christensen K, Pedersen CB, Andersen C, Kristensen BW. Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int J Clin Exp Pathol. 2013;6(4):546–60.PubMedPubMedCentral
14.
go back to reference Norregaard A, Jensen SS, Kolenda J, Aaberg-Jessen C, Christensen KG, Jensen PH, Schroder HD, Kristensen BW. Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. Neurotox Res. 2012;22(1):43–58.CrossRefPubMed Norregaard A, Jensen SS, Kolenda J, Aaberg-Jessen C, Christensen KG, Jensen PH, Schroder HD, Kristensen BW. Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. Neurotox Res. 2012;22(1):43–58.CrossRefPubMed
15.
go back to reference Halle B, Marcusson EG, Aaberg-Jessen C, Jensen SS, Meyer M, Schulz MK, Andersen C, Kristensen BW. Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. J Neurooncol. 2016;126(1):47–55. doi:10.1007/s11060-015-1947-2. Halle B, Marcusson EG, Aaberg-Jessen C, Jensen SS, Meyer M, Schulz MK, Andersen C, Kristensen BW. Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. J Neurooncol. 2016;126(1):47–55. doi:10.​1007/​s11060-015-1947-2.
16.
go back to reference Halle B, Thisgaard H, Hvidsten S, Dam JH, Aaberg-Jessen C, Thykjaer AS, Hoilund-Carlsen PF, Schulz MK, Andersen C, Kristensen BW. Estimation of tumor volumes by 11C-MeAIB and 18 F-FDG PET in an orthotopic glioblastoma rat model. J Nucl Med. 2015;56(10):1562–8.CrossRefPubMed Halle B, Thisgaard H, Hvidsten S, Dam JH, Aaberg-Jessen C, Thykjaer AS, Hoilund-Carlsen PF, Schulz MK, Andersen C, Kristensen BW. Estimation of tumor volumes by 11C-MeAIB and 18 F-FDG PET in an orthotopic glioblastoma rat model. J Nucl Med. 2015;56(10):1562–8.CrossRefPubMed
17.
go back to reference Jonhede S, Petersen A, Zetterberg M, Karlsson JO. Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells. Mol Vis. 2010;16:819–27.PubMedPubMedCentral Jonhede S, Petersen A, Zetterberg M, Karlsson JO. Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells. Mol Vis. 2010;16:819–27.PubMedPubMedCentral
18.
go back to reference Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, Tu Z, Pan F, Chang KC, Hotchkiss R, Mach RH. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer. 2012;106(4):693–701.CrossRefPubMedPubMedCentral Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, Tu Z, Pan F, Chang KC, Hotchkiss R, Mach RH. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer. 2012;106(4):693–701.CrossRefPubMedPubMedCentral
19.
go back to reference Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res. 2005;65(8):2993–5.PubMed Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res. 2005;65(8):2993–5.PubMed
20.
go back to reference Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67(2):275–82.CrossRefPubMed Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67(2):275–82.CrossRefPubMed
21.
go back to reference Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, et al. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neuro-Oncol. 2001;53(2):161–76.CrossRef Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, et al. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neuro-Oncol. 2001;53(2):161–76.CrossRef
22.
go back to reference Gliemroth J, Zulewski H, Arnold H, Terzis AJ. Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev. 2003;26(2):117–24.CrossRefPubMed Gliemroth J, Zulewski H, Arnold H, Terzis AJ. Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev. 2003;26(2):117–24.CrossRefPubMed
23.
go back to reference Terzis AJ, Pedersen PH, Feuerstein BG, Arnold H, Bjerkvig R, Deen DF. Effects of DFMO on glioma cell proliferation, migration and invasion in vitro. J Neuro-Oncol. 1998;36(2):113–21.CrossRef Terzis AJ, Pedersen PH, Feuerstein BG, Arnold H, Bjerkvig R, Deen DF. Effects of DFMO on glioma cell proliferation, migration and invasion in vitro. J Neuro-Oncol. 1998;36(2):113–21.CrossRef
24.
go back to reference Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24(3):379–93.CrossRefPubMed Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24(3):379–93.CrossRefPubMed
26.
go back to reference Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013;41(1):33–9.CrossRefPubMedPubMedCentral Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013;41(1):33–9.CrossRefPubMedPubMedCentral
Metadata
Title
Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo
Authors
Stine S. Jensen
Stine A. Petterson
Bo Halle
Charlotte Aaberg-Jessen
Bjarne W. Kristensen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3162-3

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine